This February, in honor of American Heart Month, Reliv International, a nutrition and direct selling company, is encouraging local residents to be proactive about their heart health. The proper approach, Reliv says, should include more than just avoiding certain activities and foods. "When it comes to heart health, many experts tend to focus on the 'don'ts' - don't eat red meat, don't smoke, etc., " said Dr. Carl Hastings, chief scientific officer of Reliv International. "And while there's no doubt that those steps are significant, of equal importance are the 'dos' or the positive actions that can actually prevent the onset of heart disease." Hastings says that by following the action steps below, people can gradually change their behavior and develop heart-friendly habits: - Get a physical: Although you may be feeling fine, you still may have high blood pressure or cholesterol levels that are out of whack.
Corventis Announces FDA Clearance And US Launch Of The NUVANT trade; Mobile Cardiac Telemetry System
Corventis, Inc., a developer of wireless cardiovascular solutions, announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to market its NUVANT™ Mobile Cardiac Telemetry (MCT) System for the detection of non-lethal arrhythmias. In addition, the company announced that its Monitoring Center has been approved by the Center for Medicare & Medicaid Services (CMS) as an Independent Diagnostic Testing Facility (IDTF). Corventis has also received approval to bill for services provided to patients with Medicare and several commercial insurers, paving the way for the NUVANT MCT System to be available across the United States.
NERI Research Findings Show That Erectile Dysfunction May Be Early Warning Of Future Cardiovascular Disease
In the first study of its kind, New England Research Institutes, Inc. (NERI) in collaboration with the Division of Cardiology, San Francisco General Hospital and the University of California, San Francisco tested whether erectile dysfunction (ED) can be used to reclassify patients according to their future risk of developing cardiovascular disease (CVD) beyond traditional risk factors (such as smoking, high blood pressure, high cholesterol, etc). Results of the 12-year research study are published in the January 26, 2010 issue of the Journal of the American College of Cardiology and show that ED may be a warning sign of a future cardiovascular event like heart attack, stroke, atherosclerosis, coronary artery bypass graft surgery, and congestive heart failure.
FDA Approves For Permanent Treatment Of Advanced Heart Failure Assist Device Pioneered By Texas Heart Institute At St. Luke's Episcopal Hospital
The federal Food and Drug Administration today approved a continuous-flow heart-assist device pioneered at the Texas Heart Institute (THI) at St. Luke's Episcopal Hospital (SLEH) for use as a permanent treatment for advanced heart failure. The approval of the pump device, the HeartMate II, follows several years of clinical trials and is seen as a major milestone for patients in the United States. In any given year there are some 250, 000 people who suffer from advanced heart failure, while only about 2, 000 heart transplants are performed annually in the U.S. In addition to the need far outpacing the supply of donor hearts, many patients, due to a variety of circumstances such as age and medical complications, are simply not candidates for heart transplants.
Chronic stress following Hurricane Katrina contributed to a three-fold increase in heart attacks in New Orleans more than two years after levee breaches flooded most of the city, according to researchers at Tulane University School of Medicine. Those suffering heart attacks post-Katrina also were significantly more likely to receive coronary interventions, particularly angioplasty to reopen clogged coronary arteries, which suggests these patients may have more severe disease, according to new data presented on Sunday (March 29, 2009) at the American College of Cardiology's 58th Annual Scientific Session in Orlando, Fla. The analysis is one of the first to look at the long-term impact on public health resulting from major disasters such as Hurricane Katrina.
OSA: The Sleep Disorder that's Deadly for Your Heart If you're a loud snorer who doesn't feel rested enough during the day, you may be unwittingly putting your heart at risk. That's because you could have untreated Obstructive Sleep Apnea (OSA), a disorder directly linked to several cardiovascular syndromes that cause premature death. OSA, in which the upper airway becomes blocked repeatedly during sleep, is a condition that affects 24% of men and 8% of women. Over the past 10 years, several studies have linked OSA to high blood pressure. Patients who require three or more medications to control hypertension have an 80% chance of having OSA. Also, compared to the general population the prevalence of OSA is significantly higher among patients with chronic heart failure (50% higher), a trial fibrillation (50% higher) and coronary artery disease (40% higher).
Your 3-year-old's doctor discovers a heart murmur during a visit for a mild cold with fever and recommends referral to a pediatric cardiologist. You worry and wonder how your healthy, active child could possibly have a heart problem. "Finding out that your child has a heart murmur causes a great deal of anxiety, " said Dr. Louis Bezold, associate professor of pediatrics and chief of the division of pediatric cardiology, University of Kentucky College of Medicine, and co-director of the Kentucky Children's Heart Center. "It is a common misconception that all murmurs are serious, but this is not the case. Murmurs are actually extremely common findings in infants and children.
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced that the paper "An alpha-2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine Lowering Effects and Therapeutic Response of the Beta Blocker Bucindolol in Chronic Heart Failure" was published in the January 2010 edition of the peer-reviewed journal Circulation: Heart Failure ( http://circheartfailure.ahajournals.org ). The paper concludes that in the Beta-Blocker Evaluation of Survival Trial (BEST) adrenergic polymorphism substudy, the norepinephrine lowering and clinical therapeutic responses to bucindolol were strongly influenced by the alpha-2C adrenergic receptor genotype.
Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused on Nuclear Cardiology, announced today the sale of its AttriusTM PET scanner to Manhattan based, Gramercy Cardiac Diagnostic Services, owned by prominent New York City cardiologist, Dr. Peter Rentrop. The Attrius™ is the only PET scanner on the market optimized for myocardial perfusion imaging. The Attrius™ has several specialized features making it the scanner of choice for nuclear cardiologist's who value high quality PET imagery and cardiovascular specific interpretation tools, assisting in accurately assessing the patient's condition. Joseph Oliverio, Chief Technology Officer of Positron states, "We are proud to sell Positron's newly released AttriusTM PET scanner to Dr.
A new study from Columbia University Medical Center researchers, has found that the heart's ability to pump effectively is diminished among people with a common lung disease, even in people with no or mild symptoms. Published in the Jan. 21, 2010 issue of the New England Journal of Medicine, the research is the first to show a strong link between heart function and mild COPD (chronic obstructive pulmonary disease). COPD is the fourth leading cause of death in the United States, and it is strongly associated with smoking. COPD often involves loss of lung tissue, called emphysema, as well as narrowed airways, persistent cough, and mucus production, known as chronic obstructive bronchitis.